ResMed Inc. RMD
- Market cap
- $31.9B
- P/E
- 21.3×
Follow RMD
ResMed Inc. (RMD) EV/Sales
As of 25 September 2026, ResMed Inc. (RMD) trades at a EV/Sales of 5.5×. Over the past ten years it has ranged from 3.9× (September 2015) to 13.6× (September 2021); the current reading is higher than 27% of that period. That is above the Medical Instruments & Supplies industry median of 3.1× and above the Healthcare sector median of 3.6×.
EV/Sales, daily
Annual
| Period | EV/Sales | Change |
|---|---|---|
| FY2026 | 4.8× | (33.40%) |
| FY2025 | 7.2× | 21.53% |
| FY2024 | 6.0× | (24.30%) |
| FY2023 | 7.9× | (9.39%) |
| FY2022 | 8.7× | (23.15%) |
| FY2021 | 11.3× | 17.75% |
| FY2020 | 9.6× | 33.06% |
| FY2019 | 7.2× | 13.44% |
| FY2018 | 6.4× | 16.80% |
| FY2017 | 5.5× | 11.24% |
Quarterly
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 4.8× | (14.78%) |
| Mar 2026 | 5.7× | (10.37%) |
| Dec 2025 | 6.3× | (14.89%) |
| Sep 2025 | 7.4× | 2.45% |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| MDLN Medline Inc. compare | 1.3× |
| BAX Baxter International Inc. compare | 1.7× |
| SOLV Solventum Corporation compare | 2.4× |
| BDX Becton, Dickinson and Company compare | 2.8× |
| COO The Cooper Companies, Inc. compare | 3.1× |
| ALC Alcon compare | 3.2× |
| RMD ResMed Inc. | 5.5× |
| WST West Pharmaceutical Services, Inc. compare | 7.8× |
| RGEN Repligen Corporation compare | 13.4× |
| Medical Instruments & Supplies industry median | 3.1× |
| Healthcare sector median | 3.6× |
| Market median | 2.2× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)
More on RMD
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement